Ramucirumab in Indian Patients with Advanced Gastric Cancer—Does Borderline Performance Status and Heavy Burden of Disease in Real World Practice Impact Clinical Benefit?

Ramucirumab in Indian Patients with Advanced Gastric Cancer—Does Borderline Performance Status and Heavy Burden of Disease in Real World Practice Impact Clinical Benefit?

Abstract Vikas Ostwal Background Ramucirumab is considered a standard of care as second-line therapy (CT2) in advanced gastric cancers (AGCs). The aim of this study was to assess practice patterns and...

Full description

Bibliographic Details
Main Authors: Anant Ramaswamy, Kripa Bajaj, Vineet Talwar, Kumar Prabhash, Ullas Batra, Boman Dhabhar, Mansi Sharma, Nikhil Ghadyalpatil, Satish CT, Gautam Goyal, Javvid Muzamil, Amit Bhatt, Parveen Jain, Anantbhushan Ranade, Mangesh Kamath, Jayant Pundlik Gawande, Ravi Thippeswamy, Jimmy Mirani, Neelesh Reddy, Sandip Ganguly, Sourav Kumar Mishra, Irappa Madabhavi, Shashidhara HP, Soumya Surath Panda, Shekar Patil, Prabhat Bhargava, Vikas Ostwal
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2022-01-01
Series:South Asian Journal of Cancer
Subjects:
ramucirumab
ecog ps ≥ 2
advanced gastric cancer
india
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1728980

Internet

http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1728980

Similar Items